Australian MND Therapy Moves to Phase 2 Trial
Australian MND Therapy Moves to Phase 2 Trial
Australian MND Therapy Moves to Phase 2 Trial
Key points
اہم نکات
मुख्य बातें
- An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results.
- The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons.
- A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues.
- An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results.
- The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons.
- A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues.
- An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results.
- The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons.
- A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues.
An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results. The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons. A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues. The new trial will recruit patients at six sites across Australia, including Sydney, Brisbane, Newcastle, Perth and the Sunshine Coast.
An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results. The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons. A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues. The new trial will recruit patients at six sites across Australia, including Sydney, Brisbane, Newcastle, Perth and the Sunshine Coast.
An Australian-developed therapy aimed at halting motor neurone disease is moving into a national Phase 2 clinical trial, after encouraging early results. The treatment, NUN-004 from Queensland company NuNerve, is based on more than 25 years of University of Queensland research and targets damaged motor neurons. A Phase 1 study of eight people with MND and 20 healthy volunteers found it was well tolerated with no significant safety issues. The new trial will recruit patients at six sites across Australia, including Sydney, Brisbane, Newcastle, Perth and the Sunshine Coast.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।